|No phase specified||Biomarker/Laboratory analysis, Supportive care||Active||18 to 85||NCI, Other||CDR0000660615|
MDA-2007-0914A, 2007-0914A, NCT01032278
RATIONALE: Studying samples of blood in the laboratory from patients receiving chemotherapy may help doctors identify and learn more about biomarkers related to heart damage due to chemotherapy. It may also help doctors plan the best treatment.
PURPOSE: This clinical trial is studying how well biomarkers work in detecting heart damage in patients receiving chemotherapy.
Further Study Information
- To assess the sensitivity and specificity of cardiac biomarkers, specifically B-type natriuretic peptide (BNP) and troponin I, in detecting cardiotoxicity in patients undergoing anthracycline-based chemotherapy.
- To define the sensitivity and specificity of serial LVEF measurements in detecting cardiotoxicity.
- To describe the clinical management and outcomes of patients identified with abnormal cardiac biomarkers or clinically defined cardiotoxicity during chemotherapy.
- To confirm the supportive utility of patient-reported symptoms for the development of cardiac-related toxicity.
OUTLINE: This is a multicenter study.
Patients receive anthracycline-based chemotherapy for approximately 8 courses.
Patients undergo physical exam, ECHO, EKG, and laboratory assessments, including measurement of B-type natriuretic peptide (BNP) and troponin I biomarkers, at baseline and periodically for up to 12 months. Patients also complete the M.D. Anderson Symptom Index-Heart Failure questionnaire at baseline and periodically for up to 12 months. Patients with an identified cardiac event, suspected cardiotoxicity, or abnormal biomarkers are referred to a cardiologist for treatment.
After completion of chemotherapy, patients are followed up at 6 and 12 months.
- Planning to start a new course of chemotherapy that includes an anthracycline
- Does not have to be first-line therapy
- B-type natriuretic peptide (BNP) < 200 pg/mL
- Troponin I < 0.4 ng/mL
- Life expectancy > 12 months
- Left ventricular ejection fraction (LVEF) ≥ 50%
- No unstable angina within the past 3 months
- No myocardial infarction within the past 3 months
- No decompensated heart failure within the past 3 months
- No pre-existing or prior symptomatic arrhythmia within the past 3 months
- No severe pulmonary disease (FEV ≤ 1.0 L)
- No pulmonary hypertension (mean pulmonary artery pressure ≥ 60 mm Hg)
- Not dependent on oxygen
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Prior anthracyclines allowed
- No concurrent dexrazoxane
Trial Lead Organizations/Sponsors
M. D. Anderson Cancer Center at University of TexasNational Cancer Institute
|Michael J. Fisch||Study Chair|
|M. D. Anderson Cancer Center at University of Texas|
|Clinical Trials Office - M. D. Anderson Cancer Center||Ph: 713-792-3245|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01032278
Information obtained from ClinicalTrials.gov on November 20, 2012
Back to Top